Recursion Pharmaceuticals (RXRX) has grabbed attention following the announcement of its merger with Exscientia, as well as updates on late-stage trial milestones and new regulatory clearances for ...

EPS estimates have risen 2.6% over the past 60 days, though revenue expectations have remained essentially flat over the same period. Eight analysts rate the stock a Buy, with a mean price target of ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement. The ...

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...